Tech Company Financing Transactions
Vaccinogen Funding Round
Private investors participated in a $10 million venture round for Vaccinogen. The round was announced on 8/25/2014.
Transaction Overview
Company Name
Announced On
8/25/2014
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Vaccinogen is preparing to start ACTIVE, a confirmatory Phase IIIb pivotal study of the patient-specific vaccine in patients with resectable, Stage 2 colon cancer under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA) classification.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
949 Fell St. 2nd Floor
Baltimore, MD 21231
USA
Baltimore, MD 21231
USA
Phone
Website
Email Address
Overview
Vaccinogen is a biotechnology company with more than three decades of research into combating cancer by using the body's own immune system. It is the producer of OncoVAX, the only immunotherapy for Stage II colon cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Andrew Tussing
Chief Operating Officer
Peter Morsing
Founder
Michael Hanna
Browse more venture capital transactions:
Prev: 8/25/2014: RGFREE venture capital transaction
Next: 8/25/2014: Zumigo venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs